Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Hydroxychloroquine shows no benefit in COVID-19 patients, new US Veterans study
A study conducted in US Veteran hospital in United States found no evidence that use of hydroxychloroquine (HCQ), either with or without azithromycin, reduced the risk of mechanical ventilation or death in patients hospitalized with COVID-19.
- Read more about Human trial of COVID-19 vaccine begins in the United Kingdom
From today itself, human trial of COVID-19 vaccine candidate will begin in the United Kingdom. This vaccine candidates are developed by research team of Oxford University. And they will receive initial funding of 22.2 million pound by UK government.
- Read more about NBRI scientists develop herbal hand-sanitiser
As the demand for sanitizers has increased amid coronavirus outbreak, various laboratories have started the production of sanitizers. In one such endeavour, researchers of the National Botanical Research Institute (NBRI) have developed alcohol-based herbal sanitizer. The product is developed under Council of Scientific and Industrial Research (CSIR)-Aroma Mission as per the World Health Organisation (WHO) guidelines.
- Read more about Indian researchers to go for clinical trial of sepsis drug against novel coronavirus
The Council of Scientific and Industrial Research (CSIR) is leaving no stone unturned in the battle against novel coronavirus. Repurposing of existing drugs is one of the strategies deployed by CSIR. The Council is implementing this strategy by evaluating a an existing drug that is used for treating gram-negative sepsis patients.
21 April 2020

AIOCD strongly opposes the entry of Uber in medicine delivery

AIOCD strongly oppose the entry of Uber in medicine delivery in collaboration with MedLife, an E- Pharmacy which are still illegal according to law of our country. All India Organization of Chemists and Druggists, having 8.50 lakhs Members are working day and night in this crucial time for making drugs available to our citizens, amid risky Pandemic Corona outbreak.
- Read more about 80% of COVID-19 positive people not showing symptoms, things of concern
- Read more about Antiviral remdesivir prevents disease progression in monkeys with COVID-19
This scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19. The virus shown was isolated from a patient in the U.S.NIAID-RML

Early treatment with the experimental antiviral drug remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2, the coronavirus that causes COVID-19, according to National Institutes of Health scientists.
- Read more about Investigational chimp adenovirus MERS-CoV vaccine protects monkeys
An investigational vaccine called ChAdOx1 MERS protected two groups of rhesus macaques from disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV is a relative of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19). National Institutes of Health scientists and colleagues are pursuing similar studies with ChAdOx1 SARS2, a vaccine candidate against SARS-CoV-2. They posted their results(link is external) with ChAdOx1 MERS on a preprint server. The findings are not yet peer-reviewed but are being shared to assist the public health response to COVID-19.
- Read more about EMA review of Picato concludes medicine’s risks outweigh its benefits
EMA’s safety committee (PRAC) has confirmed that Picato (ingenol mebutate), a gel for treating the skin condition actinic keratosis, may increase the risk of skin cancer and concluded that the risks of the medicine outweigh its benefits.
- Read more about How convalescent plasma therapy helpful in COVID-19?
DCGI gives permission for approval of protocol for a multi-center two arm prospective, phase-II open labeled randomized controlled trial of convalescent plasma in COVID-19 patients.